Can neuronal injury release neural antigens and promote autoantibodies?

Neuronal injury—such as traumatic brain injury or ischemic stroke—can convert normally compartmentalized CNS material into an immune-visible source of antigen. The overall claim is well supported for antigen release and subsequent autoreactivity, whereas a persistent antibody-driven inflammatory role remains biologically credible but unproven in humans.

Clinical and mechanistic evidence

• Human TBI studies detect intracellular neuronal, axonal, glial, and myelin-associated proteins—including neuron-specific enolase, UCH-L1, tau, neurofilament proteins, αII-spectrin breakdown products, and myelin basic protein—in interstitial fluid and CSF. This is consistent with cellular disruption and exposure of normally sequestered neural constituents.
• BBB disruption after TBI or ischemic stroke can expose CNS proteins and degradation products to peripheral immune surveillance. Experimental stroke data show neuronal proteins (MAP-2, NR2A) within MHC-II-positive antigen-presenting cells in cervical lymph-node T-cell zones, supporting uptake and presentation in draining immune tissue.
• Injury-associated CNS-reactive B-cell and autoantibody responses support secondary autoantibody formation; continued injury may broaden responses through epitope spreading.

Neuroinflammatory implications

• Autoantibodies could sustain inflammation if they enter the CNS, bind accessible antigen, form immune complexes, activate complement, and engage Fcγ receptors on microglia or perivascular macrophages. These pathways could amplify glial inflammatory signaling and synaptic or neuronal injury.
• This is conditional rather than established: effects depend on BBB integrity, intrathecal antibody production, antibody subclass/Fc function, antigen accessibility, and the existing glial state. Antibodies to intracellular antigens may instead be markers of prior tissue injury.

Bottom line

• Neuronal injury reliably releases immune-relevant CNS antigens and can promote secondary autoreactivity. Antibody-mediated maintenance of neuroinflammation is mechanistically plausible, but current human evidence does not establish it as an independent, sustained causal driver.